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Treatment of Vasomotor Symptoms of Menopause with Black Cohosh,
Multibotanicals, Soy, Hormone Therapy, or Placebo
A Randomized Trial
Katherine M. Newton, PhD; Susan D. Reed, MD MPH; Andrea Z. LaCroix, PhD; Louis C. Grothaus, MS; Kelly Ehrlich, MS; and
Jane Guiltinan, ND
Background: Herbal supplements are widely used for vasomotor
symptoms.
Objective: To test the efficacy of 3 herbal regimens and hormone
therapy for relief of vasomotor symptoms compared with placebo.
Design: 1-year randomized, double-blind, placebo-controlled trial
conducted from May 2001 to September 2004.
Setting: Group Health, Washington State.
Participants: 351 women age 45 to 55 years with 2 or more
vasomotor symptoms per day; 52% of the women were in meno-
pausal transition and 48% were postmenopausal.
Measurements: Rate and intensity of vasomotor symptoms (1 
mild to 3  severe), and Wiklund Vasomotor Symptom Subscale.
Interventions: 1) Black cohosh, 160 mg daily; 2) multibotanical
with black cohosh, 200 mg daily, and 9 other ingredients; 3)
multibotanical plus dietary soy counseling; 4) conjugated equine
estrogen, 0.625 mg daily, with or without medroxyprogesterone
acetate, 2.5 mg daily; or 5) placebo.
Results: Vasomotor symptoms per day, symptom intensity, Wik-
lund Vasomotor Symptom Subscale score did not differ between
the herbal interventions and placebo at 3, 6, or 12 months or for
the average over all the follow-up time points (P 0.05 for all
comparisons) with 1 exception: At 12 months, symptom intensity
was significantly worse with the multibotanical plus soy intervention
than with placebo (P 0.016). The difference in vasomotor symp-
toms per day between placebo and any of the herbal treatments at
any time point was less than 1 symptom per day; for the average
over all the follow-up time points, the difference was less than 0.55
symptom per day. The difference for hormone therapy versus pla-
cebo was 4.06 vasomotor symptoms per day for the average
over all the follow-up time points (95% CI, 5.93 to 2.19 symp-
toms per day; P 0.001).
Limitations: The trial did not simulate the whole-person approach
used by naturopathic physicians. Differences between treatment
groups smaller than 1.5 Vasomotor symptoms per day cannot be
ruled out.
Conclusion: Black cohosh used in isolation, or as part of a multi-
botanical regimen, shows little potential as an important therapy for
relief of vasomotor symptoms.
Ann Intern Med. 2006;145:869-879. www.annals.org
For author affiliations, see end of text.
Clinical Trials Registration number: NCT00169299
Hormone therapy remains the recommended treatmentfor vasomotor symptoms, but trials have shown seri-
ous risks with even short-term use (1, 2). The use of herbs,
particularly black cohosh, multibotanical supplements, and
dietary soy for menopausal symptoms has grown dramati-
cally (3–6). Few of these approaches have been scientifi-
cally evaluated. Women and providers are seeking safe, ef-
fective alternatives to hormone therapy. We designed the
Herbal Alternatives for Menopause Trial (HALT) to pro-
vide rigorous evidence on the efficacy and short-term safety
of commonly used naturopathic approaches for manage-
ment of vasomotor symptoms.
METHODS
Design Overview and Setting
HALT was a 1-year double-blind, randomized, con-
trolled trial designed to investigate the effects of 3 naturo-
pathic approaches for vasomotor symptom relief and hor-
mone therapy compared with placebo. Study methods have
been described elsewhere (7). The Group Health Institu-
tional Review Board approved this study, and a data and
safety monitoring committee monitored it. The study was
conducted at Group Health, an integrated health plan in
Washington State.
Participants
Eligibility criteria were as follows: age 45 to 55 years;
late menopausal transition (1 skipped menses within the
preceding 12 months) or postmenopausal (no bleeding
within 12 months, or follicle-stimulating hormone level
20 IU/mL if patient had undergone hysterectomy without
bilateral oophorectomy); and 2 or more vasomotor symp-
toms per day over 2 weeks (6 moderate to severe symp-
toms). Women in menopausal transition were included be-
cause many are highly symptomatic and trial data are
lacking for this group. Exclusion criteria were the follow-
ing: contraindications to hormone therapy; use of hor-
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mone therapy or oral contraceptives within 3 months be-
fore the trial; use of herbal medicines for menopausal
symptoms within 1 month before the trial; soy allergy;
bilateral oophorectomy; history of breast cancer; and non-
adherence during the run-in period (80% of capsules
taken).
From May 2001 through August 2003, women were
recruited by using direct mail. Screening calls determined
initial eligibility. Women attended an orientation visit at
which eligibility was confirmed, physical measurements
were collected, and placebo medication and questionnaires
for the 2-week run-in period were provided.
Randomization and Interventions
Participants were randomly assigned by using SAS
software (SAS Institute, Inc., Cary, North Carolina), strat-
ified by previous hormone therapy and hysterectomy;
block sizes within strata ranged from 5 to 25. Treatment
assignments were sent to the University of Washington
Research Pharmacy, where medications were bottled and
labeled with a sequential identification number without
treatment group indication. At the randomization visit, va-
somotor symptom diaries and medication counts were ex-
amined to confirm eligibility and adherence. The study
nurse determined the appropriate stratum, assigned the
participant the next study number in that stratum without
knowledge of group assignment, and distributed study
medications.
The publication of results from the Women’s Health
Initiative (WHI) estrogen–progestin trial (2) raised new
concerns about the safety of estrogen therapy. New study
participants were given the choice of 5-arm (including hor-
mone therapy) versus 4-arm (no hormone therapy) ran-
domization. Current participants gave consent again, in-
corporating risk estimates from the WHI, and were given
the option of finding out whether they had been assigned
to hormone therapy; 16 were unblinded, 1 discontinued
use of the study drug, and all remained enrolled. Following
publication of the WHI Memory Study (8, 9), we in-
formed participants of those findings and restricted ran-
domization to herbs and placebo. No further women were
unblinded or discontinued use of the study drug.
Naturopathic medicine provided the model for study
interventions. The herbal products, doses, and soy diet
were based on approaches used by naturopaths when the
study was designed (7). The study groups were as follows:
1) black cohosh (Actaea racemosa or Cimicifuga racemosa,
160 mg daily; 2.5% triterpene glycosides; 70% ethanol
extract); 2) multibotanical; 3) multibotanical plus soy diet
counseling; 4) conjugated equine estrogen, 0.625 mg daily,
with (for women with a uterus) or without (for women
without a uterus) medroxyprogesterone acetate, 2.5 mg;
and 5) placebo. The multibotanical delivered daily doses of
the following: black cohosh, 200 mg; alfalfa (Medicago sa-
tiva), 400 mg; boron, 4 mg; chaste tree (Vitex agnus-castus),
200 mg; dong quai (Angelica sinensis), 400 mg; false uni-
corn (Chamaelirium luteum), 200 mg; licorice (Glycyrrhiza
glabra), 200 mg; oats (Avena sativa), 400 mg; pomegranate
(Punica granatum), 400 mg; Siberian ginseng (Eleutherococ-
cus senticosus, standardized constituents 0.8% eleuthero-
sides E and B), 400 mg.
Black cohosh was provided by Pure World, Inc.,
(Hackensack, New Jersey). The multibotanical, ProGyne,
was purchased from Progena Professional Formulations
(Albuquerque, New Mexico) and encapsulated to study
specifications. Both companies follow current good manu-
facturing practices, and single batches were used. Consumer
Lab.com (White Plains, New York) tested the products
after the study commenced. Dong quai, false unicorn, and
pomegranate were not detected, suggesting that they were
of poor quality or did not contain the tested marker com-
pounds. Other marker compounds were detected in the
approximate doses as labeled (7). The Appendix Table
(available at www.annals.org) describes the herbal products
in detail.
To facilitate blinding, medications and lactose placebo
were encapsulated to provide 2 white and 2 blue capsules
to each woman, and medication boxes were labeled with a
unique identification number that did not indicate study
group.
The soy food intervention was modeled after a success-
ful 5-a-day intervention (10). We chose soy foods because
of uncertainty about the efficacy of isoflavone supplements
and because naturopaths commonly recommend whole soy
foods. Participants received 5 telephone calls from a clini-
cal dietitian and a 34-page booklet recommending 2 soy
Context
Caution about taking estrogen for treating postmeno-
pausal vasomotor symptoms has led to increasing
substitution of herbal regimens despite few tests of their
effectiveness.
Contribution
The authors randomly assigned 351 perimenopausal or
postmenopausal women to herbal treatments (black co-
hosh, multibotanicals, or multibotanicals plus counseling
about dietary soy), estrogen with or without progesterone,
or placebo. At 3, 6, and 12 months, patients receiving the
herbal interventions had the same change in vasomotor
symptoms as those receiving placebo (except for more
severe symptoms at 12 months for patients taking multi-
botanicals plus dietary soy). Estrogen substantially de-
creased vasomotor symptoms.
Cautions
Most participants were white and were well-educated.
Implications
Herbal regimens did not reduce postmenopausal vasomo-
tor symptoms in this sample of women.
—The Editors
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food servings per day (12 to 20 g of soy protein) (7). Other
participants received 1 telephone call and a similar booklet
reinforcing fruit and vegetable intake. Participants were in-
structed not to discuss dietitian calls with study nurses and
were unaware that soy counseling was linked to the multi-
botanical.
Outcomes and Measurements
The primary outcomes were change from baseline
(measured over 2-week run-in period) to 3, 6, and 12
months (each measured for 4 weeks) and change from
baseline to the average for all follow-ups with regard to the
mean frequency and intensity of vasomotor symptoms
(daytime hot flashes plus night sweats) and the mean Wik-
lund Vasomotor Symptom Subscale score (11, 12). We
also evaluated change from baseline to follow-up (months
3, 6, and 12 and average change) for daytime hot flash rate,
night sweat rate, and the total Wiklund Menopause Symp-
tom Scale score. Symptom diaries and global ratings of
menopause symptoms are almost universally used in stud-
ies of vasomotor symptoms. Participants used a vasomotor
symptom diary to record daytime hot flashes and night
sweats, rating intensity as mild, moderate, or severe (scale,
1 to 3), as recommended by the U.S. Food and Drug
Administration (13). Women completed the Wiklund
Menopause Symptom Scale, rating the severity of 13
menopausal symptoms (sweats, hot flashes, sleep distur-
bance, fatigue, vaginal dryness, depression, headache, irri-
tability, muscle/joint pain, breast tenderness, nervousness,
palpitations, and dizziness/fainting on a scale of 0 (none)
to 10 (severe) (11). Soy food intake was monitored by
using a self-reported, validated soy food questionnaire (14).
Follow-up Procedures
Participants returned to the research clinic at 3, 6, and
12 months. Questionnaires were collected, and study med-
ication was dispensed. Medication adherence counts were
conducted by staff without participant contact and without
knowledge of treatment assignment. Study nurses encour-
aged adherence and monitored adverse events during
monthly telephone calls and at visits. Adverse events were
identified through participants’ responses to the question,
“Have you had any medical problems or been hospital-
ized?” Responses were recorded and adverse events were
followed until they were resolved. The study nurse deter-
mined intensity (mild, moderate, or severe) and whether
the event was serious (yes or no). Events were reviewed by
the study physician, who determined whether the event
was study related, without knowledge of group assignment.
Adverse events were coded by using the Coding Symbols for
Thesaurus of Adverse Reaction Terms (15).
The Data and Safety Monitoring Committee reviewed
study progress and unblinded outcome and safety data 5
times.
Statistical Analysis
The study was powered to detect an effect of herbs
halfway between the expected effects of hormone therapy
and placebo, an outcome that we hypothesized would be
meaningful.
Treatment effects, the difference between each treat-
ment group and the placebo group with regard to the mean
change from baseline, and the associated 95% CIs and P
values were estimated by using a multivariate mixed model
(PROC MIXED in SAS). We used an unstructured covari-
ance matrix for the repeated measures, with separate pa-
rameter estimates for women in the hormone therapy
group, since this structure best fit the data. Mixed models
increase statistical power because of their ability to use all
follow-up data and to better handle missing data. Although
retention rates were very high, mixed-model analysis al-
lowed us to use a true intention-to-treat approach, includ-
ing data from all 351 randomly assigned women (n  349
in adjusted analyses because of missing covariate data). The
two Wiklund measures were analyzed after square-root
transformation to normalize their distributions.
Mixed models were evaluated with and without ad-
justment for covariates. All models included a term for
randomization protocol (4-arm vs. 5-arm). The adjusted
models also controlled for age, body mass index (BMI),
hysterectomy, menopausal status (menopausal transition
vs. postmenopausal), and previous hormone therapy. All
covariates except for BMI were selected a priori because of
their hypothesized correlations with study outcomes and
exposures. Results from the adjusted and unadjusted mod-
els were identical; we present only the adjusted results.
We also tested whether treatment effects differed by
4-arm versus 5-arm randomization (arm by-treatment in-
teraction). Since they did not differ, we present the results
based on all randomly assigned women. An “as-treated”
sensitivity analysis, restricted to women who took at least
80% of their study medications, was conducted, but results
were similar and are not presented. Finally, we used mixed
models to test whether the effect of each treatment varied
in a statistically significant manner with BMI (nonobese
[BMI 30 kg/m2] vs. obese), hysterectomy, menopausal
status, previous use of hormone therapy, and baseline
symptom rate (7 symptoms per day vs. 7 symptoms
per day).
Adverse events rates were compared between each
group and placebo by using chi-square tests or Fisher exact
test (if expected count was 5). The study biostatistician
conducted all analyses.
Role of the Funding Sources
This study was funded by the National Institute on
Aging and National Center for Complementary and Alter-
native Medicine. These agencies did not participate in the
design, conduct, or analysis of the study or in decisions to
submit the manuscript for publication. The National In-
stitute on Aging did participate in decisions related to re-
cruitment redesign in response to the release of the WHI
findings and had a representative who attended all Data
and Safety Monitoring Committee meetings.
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RESULTS
Participants and Follow-up
We mailed 157 493 informational brochures and re-
ceived 3443 responses (Figure 1). The baseline visit was
attended by 509 women; of the 398 eligible women, 351
consented and were randomly assigned as follows: black
cohosh (n  80); multibotanical (n  76); multibotanical
plus soy counseling (n  79); conjugated equine estrogen
with medroxyprogesterone acetate (n  29 women with a
uterus) or without medroxyprogesterone acetate (n  3
women without a uterus, all receiving unopposed estro-
gen); or placebo (n  84). We enrolled 159 women under
the 5-arm randomization scheme and 192 under the 4-arm
randomization scheme; 147 of 183 women who were given
a choice selected the 4-arm protocol. Ninety-two percent
of women completed the study (327 of 351), and 87%
(306 of 351) were taking study medication at 12 months.
Baseline characteristics were similar across treatment
groups, with the exception of BMI (Table 1). On average,
BMI was lower in the black cohosh group than in the
placebo group and was higher in the hormone therapy
group than in the placebo group. Average age was 52.2
years; 93% of participants were white, and all had at least
a high school education. Women averaged 6.5 vasomotor
symptoms per day (SD, 3.7; range, 1.4 to 24), and 34%
averaged at least 7 symptoms per day at baseline. Average
symptom intensity was 1.8 (on a scale of 1 to 3); 29% of
participants reported symptom intensity averaging at least
2.0. The average Wiklund Menopause Symptom Scale
score was 2.3 (SD, 1.2; range, 0.2 to 6.5) and the average
Wiklund Vasomotor Symptom Subscale score was 4.5
(SD, 2.0; range, 0.8 to 10). Of 183 women (52%) who
were in menopausal transition at baseline, 79 (46.6%)
achieved 12 months of amenorrhea during the study.
Among women assigned to the soy food intervention,
77% completed 3 or more telephone calls (mean, 3.6). At
baseline, women reported an average of 0.6 serving of soy
per day. On average, women in the multibotanical plus soy
intervention increased dietary soy by 1.1 servings per day
between baseline and 3 months, compared with 0.1 serving
per day in the other 4 groups.
Primary Outcomes
The average adjusted number of vasomotor symptoms
per day (Figure 2) and the Wiklund Vasomotor Symptom
Subscale score (Figure 3) decreased between baseline and 3
months in all groups. There were no statistically significant
differences in the average adjusted change in vasomotor
symptoms per day or in vasomotor symptom intensity be-
tween the herbal interventions and placebo at 3, 6, or 12
months, or for the average over all the follow-up time
points, with 1 exception: At 12 months, the multibotanical
plus soy intervention had higher (worse) symptom inten-
sity relative to placebo (P  0.016) (Table 2). The average
difference in vasomotor symptoms per day between the
placebo and herbal treatments groups was less than 1
symptom per day at 3 months and less than 0.6 symptom
per day for the average over all the follow-up time points.
The average adjusted difference for hormone therapy com-
pared with placebo was 4.55 (95% CI, 6.51
to 2.59) vasomotor symptoms per day at 3 months (P 
0.001) and 4.06 (CI, 5.93 to 2.19) vasomotor
symptoms per day for the average over all the follow-up
time points (P  0.001) (Table 2).
There were no statistically significant differences in the
Wiklund Vasomotor Symptom Subscale score between any
of the herbal interventions and placebo at 3, 6, or 12
months or for the average over all the follow-up time
points (Table 2). The Wiklund Vasomotor Symptom Sub-
scale score was statistically significantly lower with hor-
mone therapy than with placebo at all follow-up time
points.
Additional Analyses
There were no statistically significant differences in
hot flashes per day or night sweats per day between any of
the herbal interventions and placebo at 3, 6, or 12 months
or for the average over all the time points, with 1 excep-
tion: At 3 months, the black cohosh group had 0.38 less
night sweat per day than the placebo group (CI, 0.72
to 0.04; P  0.030) (Table 3). The difference between
the herbal treatments and placebo was less than 0.6 hot
flash per day and less than 0.4 night sweat per day at any
time point; the differences in the average over all the time
points were even smaller. The differences in hot flashes per
day and night sweats per day between hormone therapy
and placebo were statistically significant at all times points;
over all follow-up time points, the average difference was
nearly 3 hot flashes per day and nearly 1 night sweat
per day (Table 3).
There were no statistically significant differences in the
Wiklund Menopause Symptom Scale score between any of
the herbal interventions and placebo at 3, 6, or 12 months
or for the average over all the time points (Table 3). All
differences between hormone therapy and placebo were
statistically significant at all times (Table 3).
As-treated analyses, limited to women with at least
80% adherence, and separate analyses for women in the
4-arm and 5-arm randomization schemes, yielded similar
results (data not shown). Results did not vary (no statisti-
cally significant treatment by subgroup interaction) when
results were examined by baseline number of vasomotor
symptoms (7 vs. 7 per day), 4-arm versus 5-arm ran-
domization scheme, baseline menopausal status, previous
use of hormone therapy, hysterectomy (yes or no), or BMI
(not obese [30 kg/m2] vs. obese) (data not shown).
Adverse Events and Adherence
Women assigned to hormone therapy reported more
breast pain (P  0.001) and menstrual disorders (P 
0.04) compared with placebo (Table 4). There were no
statistically significant differences between any of the 4
groups and placebo in the proportion of women with up-
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Figure 1. Participant recruitment and retention, Herbal Alternatives for Menopause Trial (HALT).
Reasons for discontinuing therapy are not mutually exclusive. All participants received allocated intervention. *In the original enrolled plan, all
participants were enrolled in 1 of 5 groups. †After publication of the Women’s Health Initiative (WHI) estrogen–progestin (E P) trial (2), women were
given the option of 4-arm (without conjugated equine estrogen [CEE]) or 5-arm randomization. ‡After publication of the WHI Memory Study (8, 9),
randomization to CEE was stopped and only 4-arm randomization (that is, random assignment to herb or placebo, excluding hormone therapy) was used.
BMD  bone mineral density; FSH  follicle-stimulating hormone; HT  estrogen with or without progestin; MPA  medroxyprogesterone acetate,
2.5 mg (women without a uterus were randomly assigned to CEE only); soy  counseling to increase dietary soy; TSH  thyroid-stimulating hormone.
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per or lower gastrointestinal symptoms; nausea and vomit-
ing; fatigue, asthenia, or malaise; or headaches or migraine.
Too few severe adverse events occurred to make meaning-
ful group comparisons (1 case of endometrial cancer in the
multibotanical plus soy group 2.8 months after randomiza-
tion; 1 case of breast cancer in the multibotanical group
4.7 months after randomization).
Over the 12-month follow-up period, the overall study
sample on average took 86% of their pills; among individ-
ual study groups, adherence was 88% for black cohosh,
80% for multibotanical, 87% for multibotanical plus soy,
87% for hormone therapy, and 82% for placebo. These
adherence figures include all 351 women; adherence was
set to 0 for those who dropped out or stopped using study
medication (Table 4). The primary reasons for discontin-
uation of study medication use or study withdrawal were
no symptom relief (n  10), other symptoms (n  8), or
change in health status (n  8) (Figure 1).
Table 1. Baseline Clinical and Demographic Characteristics by Randomization Group
Characteristic All Participants
(n  351)
Black Cohosh
Group
(n  80)
Multibotanical
Group
(n  76)
Multibotanical
plus Soy
Counseling
Group
(n  79)
Conjugated
Equine Estrogen
with or without
Medroxyprogesterone
Acetate Group
(n  32)
Placebo
Group
(n  84)
Mean age (SD), y 52.2 (2.4) 52.0 (2.2) 52.2 (2.5) 52.5 (2.5) 52.3 (2.6) 52.0 (2.5)
Mean body mass index (SD), kg/m2 28.6 (6.2) 27.3 (5.0) 28.4 (6.3) 28.4 (5.7) 31.5 (7.9) 29.2 (6.4)
Race/ethnicity, n (%)
White 323 (93) 73 (91) 72 (99) 74 (95) 30 (94) 74 (88)
African-American 9 (3) 3 (4) 1 (1) 3 (4) 0 (0) 2 (2)
Other 15 (4) 4 (5) 0 (0) 1 (1) 2(6) 8 (10)
Greater than high school education, n (%) 331 (95) 77 (96) 72 (97) 75 (95) 28 (88) 79 (94)
Menopausal transition (vs. postmenopausal),
n (%)
183 (52) 39 (49) 39 (52) 43 (54) 20 (63) 42 (50)
Hysterectomy*, n (%) 38 (11) 9 (11) 7 (9) 8 (10) 3 (9) 11(13)
Previous hormone therapy, n (%) 140 (40) 32 (40) 31 (41) 32 (41) 10 (31) 35 (42)
Mean vasomotor symptoms per day (SD), n 6.5 (3.7) 6.7 (3.0) 6.2 (3.6) 6.5 (3.9) 6.8 (4.9) 6.2 (3.7)
Hot flashes 4.6 (3.1) 4.7 (2.5) 4.4 (3.0) 4.6 (3.2) 5.0 (4.4) 4.3 (3.0)
Night sweats 1.9 (1.2) 2.0 (1.2) 1.8 (1.1) 1.9 (1.2) 1.8 (1.0) 1.9 (1.2)
Mean vasomotor symptom intensity (SD)† 1.80 (0.39) 1.78 (0.39) 1.78 (0.39) 1.77 (0.35) 1.82 (0.40) 1.85 (0.41)
Average symptoms moderate to severe
(vs. mild), n (%)
101 (29) 21 (26) 20 (28) 22 (26) 12 (38) 26 (31)
Mean Wiklund Menopause Symptom score (SD) 2.3 (1.2) 2.2 (1.2) 2.2 (1.1) 2.2 (1.2) 2.1 (1.0) 2.5 (1.2)
Mean Wiklund Vasomotor Symptom
Subscale score (SD)
4.5 (2.0) 4.4 (1.9) 4.3 (1.9) 4.3 (2.1) 4.5 (2.0) 4.9 (2.0)
Average 7 vasomotor symptoms per day,
n (%)
120 (34) 33 (41) 23 (30) 28 (35) 12 (38) 24 (29)
* Women with hysterectomy had at least 1 ovary.
† 1  mild; 2  moderate; 3  severe.
Figure 2. Adjusted mean number of vasomotor symptoms
per day, by study group.
Adjusted for age (continuous), body mass index (kg/m2, continuous),
hysterectomy (yes or no), previous use of hormone therapy (HT) (yes or
no), menopausal status (menopausal transition vs. postmenopausal), and
randomization arm (4-arm without hormone therapy vs. 5-arm with
hormone therapy).
Figure 3. Adjusted mean Wiklund Vasomotor Symptom
Subscale scores, by study group.
Adjusted for age (continuous), body mass index (kg/m2, continuous),
hysterectomy (yes or no), previous use of hormone therapy (HT) (yes or
no), menopausal status (menopausal transition vs. postmenopausal), and
randomization arm (4-arm without hormone therapy vs. 5-arm with
hormone therapy).
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DISCUSSION
In this large, randomized, double-blind trial, none of
the 3 herbal treatments had clinically meaningful effects on
any of the primary outcomes. As expected, hormone ther-
apy resulted in a clinically important decrease in vasomotor
symptom frequency and Wiklund scores throughout 1 year
of treatment.
At least 5 randomized, placebo-controlled trials of
black cohosh and menopausal symptoms have been pub-
lished (16–20). All were short-term (12 weeks), and
most were small, typically randomly assigning 30 to 60
women per group. Among 5 trials that examined frequency
of hot flashes (16–19, 21), the only trial reporting a posi-
tive effect for black cohosh also found no effect of conju-
gated equine estrogen versus placebo (18); this result raises
concerns about the validity of the findings. When meno-
pause rating scales were used, 2 trials reported a positive
effect of black cohosh (16, 18), 3 reported no difference
from placebo (17, 19, 21) , and 1 did not report main trial
effects (20). The only trial that investigated a multibotani-
cal containing black cohosh found no differences in vaso-
motor symptom frequency or menopause scale scores com-
Table 2. Difference in Adjusted Mean Change in Vasomotor Symptom Frequency and Intensity and Wiklund Vasomotor Symptom
Subscale Score between Intervention and Placebo Groups*
Variable Black Cohosh Group
(n  80)
Multibotanical Group
(n  76)
Multibotanical plus Soy
Counseling Group
(n  79)
Conjugated Equine Estrogen
with or without
Medroxyprogesterone Acetate
Group (n  32)
Difference in Mean
Change vs. Placebo
(95% CI)
P Value
vs.
Placebo
Difference in Mean
Change vs. Placebo
(95% CI)
P Value
vs.
Placebo
Difference in Mean
Change vs. Placebo
(95% CI)
P Value
vs.
Placebo
Difference in Mean
Change vs.
Placebo (95% CI)
P Value
vs.
Placebo
Vasomotor symptoms
per day (hot
flashes plus
night sweats)
3 mo –0.96
(–2.03 to 0.11)
0.079 0.41
(–0.67 to 1.50)
0.45 –0.53
(–1.60 to 0.54)
0.33 –4.55
(–6.51 to –2.59)
0.001
6 mo –0.48
(–1.63 to 0.66)
0.41 0.80
(–0.36 to 1.96)
0.178 0.32
(–0.83 to 1.47)
0.59 –3.86
(–5.73 to –2.00)
0.001
12 mo –0.18
(–1.30 to 0.93)
0.74 0.09
(–1.03 to 1.20)
0.88 0.49
(–0.62 to 1.60)
0.39 –3.76
(–5.76 to –1.76)
0.001
Treatment effect
over all follow-up
time points
–0.54
(–1.47 to 0.38)
0.25 0.43
(–0.50 to 1.37)
0.36 0.09
(–0.83 to 1.02)
0.84 –4.06
(–5.93 to –2.19)
0.001
Vasomotor symptom
intensity
(1  mild,
2  moderate,
3  severe)
3 mo 0.03
(–0.08 to 0.14)
0.59 0.08
(–0.03 to 0.19)
0.174 0.03
(–0.08 to 0.14)
0.60 0.07
(–0.17 to 0.31)
0.57
6 mo 0.01
(–0.11 to 0.12)
0.91 0.09
(–0.03 to 0.21)
0.126 0.06
(–0.06 to 0.17)
0.35 –0.13
(–0.34 to 0.08)
0.23
12 mo 0.05
(–0.07 to 0.17)
0.46 0.11
(–0.02 to 0.23)
0.089 0.15
(0.03 to 0.27)
0.016 0.05
(–0.15 to 0.26)
0.63
Treatment effect
over all follow-up
time points
0.03
(–0.07 to 0.12)
0.57 0.09
(0.00 to 0.19)
0.063 0.08
(–0.02 to 0.17)
0.108 0.00
(–0.19 to 0.18)
0.97
Wiklund Vasomotor
Symptom
Subscale score
3 mo –0.47
(–1.18 to 0.24)
0.098 0.15
(–0.57 to 0.87)
0.88 –0.23
(–0.94 to 0.48)
0.28 –2.60
(–3.74 to –1.46)
0.001
6 mo 0.20
(–0.52 to 0.91)
0.90 0.80
(0.07 to 1.52)
0.062 0.72
(–0.01 to 1.44)
0.057 –1.78
(–2.80 to –0.76)
0.001
12 mo 0.10
(–0.68 to 0.88)
0.83 0.44
(–0.34 to 1.22)
0.43 0.57
(–0.21 to 1.35)
0.27 –1.77
(–2.79 to –0.75)
0.001
Treatment effect
over all follow-up
time points
–0.06
(–0.67 to 0.55)
0.48 0.46
(–0.15 to 1.08)
0.30 0.35
(–0.26 to 0.96)
0.41 –2.05
(–3.02 to –1.08)
0.001
* All analyses were adjusted for age (continuous), body mass index (kg/m2, continuous), hysterectomy (yes or no), previous use of hormone therapy (yes or no), menopausal
status (menopause transition vs. postmenopausal), and randomization arm (4-arm without hormone therapy vs. 5-arm with hormone therapy). Estimates of difference in
mean change from baseline vs. placebo, along with P values and 95% CIs, from mixed-model analysis that used data from baseline and all 3 follow-up time points (total, n 
349 for adjusted analyses).
ArticleHerbal Alternatives for Menopause Trial
www.annals.org 19 December 2006 Annals of Internal Medicine Volume 145 • Number 12 875
Downloaded from https://annals.org by University of California San Diego user on 07/01/2019
pared with placebo (22). Thus, the totality of the evidence
does not consistently support a short-term effect of black
cohosh on menopausal symptoms.
Effects of herbal products, such as black cohosh, may
be sensitive to dose, extraction method, plant type, and
coadministration of other herbs. The total daily triterpene
glycoside dose in our black cohosh product was 5 mg,
comparable to the 2 to 4 mg found in Remifemin (Schaper
& Bru¨mmer GmbH, Salzgitter, Germany), the most
widely used product. Like Remifemin, our black cohosh
(fingerprinted and verified to be Actaea racemosa) (7) was
standardized to 27-deoxyactin. Remifemin is an isopropyl
alcohol extract, whereas the products we tested are ethanol
extracts. The implications of these different extraction
techniques are unknown.
The literature on the other ingredients in the multi-
botanical is limited. Randomized trials have shown no im-
provement in vasomotor symptoms with dong quai (23) or
Siberian ginseng (24). We are unaware of any study that
has examined how the other components of the multibo-
tanical affect vasomotor symptoms, although similar for-
mulas are prescribed by naturopathic clinicians (7) and
sold as over-the-counter supplements.
We reviewed 16 randomized clinical trials that tested
whole soy or soy isoflavone supplements for vasomotor
symptoms (25–40). Most were 12-week trials (range, 4 to
Table 3. Difference in Adjusted Mean Change in Frequency of Hot Flashes and Night Sweats and Wiklund Menopause Symptom
Scale Scores between Intervention and Placebo Groups*
Variable Black Cohosh Group
(n  80)
Multibotanical Group
(n  76)
Multibotanical plus Soy
Counseling Group
(n  79)
Conjugated Equine Estrogen
with or without
Medroxyprogesterone Acetate
Group (n  32)
Difference in Mean
Change vs. Placebo
(95%CI)
P Value
vs.
Placebo
Difference in Mean
Change vs. Placebo
(95%CI)
P Value
vs.
Placebo
Difference in Mean
Change vs. Placebo
(95%CI)
P Value
vs.
Placebo
Difference in Mean
Change vs. Placebo
(95%CI)
P Value
vs.
Placebo
Hot flashes per day
3 mo –0.59
(–1.43 to 0.26)
0.174 0.30
(–0.56 to 1.15)
0.50 –0.34
(–1.19 to 0.50)
0.42 –3.55
(–5.24 to –1.86)
0.0002
6 mo –0.26
(–1.19 to 0.67)
0.59 0.55
(–0.40 to 1.50)
0.26 0.32
(–0.62 to 1.26)
0.51 –2.89
(–4.52 to –1.26)
0.001
12 mo –0.28
(–1.16 to 0.60)
0.53 –0.05
(–0.93 to 0.84)
0.92 0.32
(–0.56 to 1.20)
0.48 –3.15
(–4.84 to –1.47)
0.001
Treatment effect
over all
follow-up time
points
–0.38
(–1.13 to 0.37)
0.33 0.27
(–0.49 to 1.03)
0.49 0.10
(–0.65 to 0.85)
0.80 –3.20
(–4.82 to –1.58)
0.001
Night sweats per
day
3 mo –0.38
(–0.72 to –0.04)
0.030 0.11
(–0.23 to 0.46)
0.52 –0.18
(–0.53 to 0.16)
0.29 –0.98
(–1.40 to –0.56)
0.001
6 mo –0.23
(–0.57 to 0.11)
0.182 0.23
(–0.12 to 0.57)
0.198 0.00
(–0.34 to 0.34)
1.00 –0.98
(–1.40 to –0.56)
0.001
12 mo 0.08
(–0.30 to 0.47)
0.67 0.12
(–0.27 to 0.51)
0.54 0.16
(–0.23 to 0.54)
0.43 –0.60
(–1.08 to –0.13)
0.015
Treatment effect
over all
follow-up time
points
–0.18
(–0.48 to 0.12)
0.25 0.15
(–0.15 to 0.46)
0.32 –0.01
(–0.31 to 0.29)
0.95 –0.85
(–1.26 to –0.45)
0.001
Wiklund Meno-
pause Symp-
tom Subscale
score
3 mo –0.15
(–0.47 to 0.17)
0.23 –0.04
(–0.36 to 0.28)
0.57 –0.10
(–0.42 to 0.22)
0.35 –0.87
(–1.29 to –0.46)
0.001
6 mo 0.07
(–0.26 to 0.41)
0.86 0.35
(0.01 to 0.68)
0.068 0.25
(–0.08 to 0.58)
0.23 –0.37
(–0.90 to 0.16)
0.028
12 mo –0.03
(–0.40 to 0.33)
0.83 0.14
(–0.23 to 0.51)
0.54 0.03
(–0.34 to 0.40)
0.99 –0.49
(–0.93 to –0.05)
0.013
Treatment effect
over all
follow-up time
points
–0.04
(–0.33 to 0.26)
0.64 0.15
(–0.15 to 0.44)
0.45 0.06
(–0.23 to 0.35)
0.90 –0.58
(–0.98 to –0.18)
0.001
* All analyses were adjusted for age (continuous), body mass index (kg/m2, continuous), hysterectomy (yes or no), previous use of hormone therapy (yes or no), menopausal
status (menopause transition vs. postmenopausal), and randomization arm (4-arm without hormone therapy vs. 5-arm with hormone therapy). Estimates of difference in
mean change from baseline vs. placebo, along with P values and 95% CIs, from mixed-model analysis that used data from baseline and all 3 follow-up time points (total, n 
349 for adjusted analyses).
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52). Eight studies found statistically significant improve-
ments in at least 1 menopause symptom measure (26–28,
31, 33, 35, 37, 39). The magnitude of benefit was a 25%
to 55% decrease in frequency or severity of menopause
symptoms. Only 3 short-term studies evaluated dietary soy
and vasomotor symptoms (38–40); 1 found a statistically
significant improvement in vasomotor symptoms after 12
weeks of a soy- and flax-enriched diet (39).
To our knowledge, ours is the longest and largest pla-
cebo-controlled, double-blind trial to date, and we in-
cluded both placebo and hormone therapy as benchmark
comparison groups. Findings from our study indicate that
trials longer than 12 weeks are necessary to evaluate the
sustainability of effects. Adherence and retention were
high. We included women in the menopausal transition,
and women with 2 or more vasomotor symptoms per day
(compared with the 7 to 8 required in Food and Drug
Administration–monitored drug trials [13]), because
women with fewer symptoms are a key target for herbal
therapies. Our findings were similar for women with 7 or
more versus fewer than 7 symptoms per day. Although we
found no evidence of significant side effects, only a larger
and longer trial could provide reassurance in this regard.
Our results are generalizable to white, relatively well-edu-
cated women who have an average of at least 2 vasomotor
symptoms per day. We conducted independent testing of
the herbal products; no contaminants were found, and key
constituents were present in the amounts specified by the
manufacturers (7).
An important question in a trial that does not find
statistically significant treatment effects is whether the neg-
ative findings were due to a true lack of clinically impor-
tant effects or a lack of statistical power. The confidence
intervals for our primary outcome of symptoms per day
can be used to determine the effect size that can be “ruled
out” by our results (Table 2). Over all 3 follow-up time
points, one can rule out reductions beyond 1.5 symptoms
per day from black cohosh and 1.0 symptom per day from
the multibotanical treatments. Whether these are clinically
important effects is debatable, but we would argue that
most women would not think so. It is important to em-
phasize that these are the largest possible effects that are
consistent with our data. Our best estimates of effect are
far less; the average reduction in symptoms per day over
the entire follow-up period was less than 0.01 symptom
per day, combining results for the 3 herbal groups, all of
whom received black cohosh.
Treatments used in naturopathic practice motivated
our choice of interventions. The whole-person approach
used by most naturopathic physicians differs significantly
from the treatments selected for our study, and this might
have affected response to therapy. Time spent with the
patient on counseling about diet, exercise, and emotional
issues related to menopause; dose revisions; and additional
supplements are important aspects of the naturopathic
strategy for managing menopausal symptoms. We could
not replicate this approach.
In summary, there is a pressing need for safe and ef-
fective interventions for vasomotor symptoms. Regrettably,
this trial and the totality of the evidence indicates that
black cohosh used in isolation, or in a multibotanical prod-
uct, has little potential to play an important role in relief of
vasomotor symptoms.
Table 4. Women with Adverse Events, Mean Adherence, and Reasons for Withdrawal or Discontinuation of Medication Use by
Treatment Group over 12 Months of Follow-up
Variable Black Cohosh
Group
(n  80)
Multibotanical
Group
(n  76)
Multibotanical plus Soy
Counseling Group
(n  79)
Conjugated Equine
Estrogen with or without
Medroxyprogesterone
Acetate Group (n  32)
Placebo Group
(n  84)
Adverse events
Menstrual disorders, n (%) 10 (13) 8 (11) 14 (18) 19 (59)* 17 (20)
Breast discomfort, n (%) 0 1 (1) 2 (3) 5 (16)† 3 (4)
Gastrointestinal upset, n (%) 12 (15) 11 (14) 8 (10) 4 (13) 13 (15)
Headache, n (%) 12 (15) 8 (11) 12 (15) 6 (19) 16 (19)
Fatigue, asthenia, or malaise, n (%) 12 (15) 7 (9) 12 (15) 6 (19) 8 (10)
Myalgia or arthralgia, n (%) 11 (14) 9 (12) 9 (11) 1 (3) 10 (12)
Adherence
Average medications taken, % 88 80 87 87 82
Reasons for study medication
discontinuation or study withdrawal,
n (%)
No symptom relief 1 (1.3) 5 (6.6) 2 (2.5) 1 (3.1) 1 (1.2)
Other symptoms 1 (1.3) 1 (1.3) – 4 (12.5) 2 (2.4)
Change in health status – – 4 (5.1) 1 (3.1) 3 (3.6)
Other 5 (6.3) 3 (3.9) 4 (5.1) 2 (6.3) 5 (6.0)
* P  0.001 vs. placebo.
† P  0.04 vs. placebo.
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Appendix Table. Consolidated Standards of Reporting Trials (CONSORT) Requirements for Controlled Trials of Herbal
Interventions*
Criteria
Black Cohosh:
Single Herb Product
Multibotanical Product
Black Cohosh Alfalfa Boron Citrate
Latin binomial name Actaea rasemosa Actaea rasemosa Medicago sativa NA
Botanical authority NA
Family name Ranuculaceae Ranuculaceae Fabaceae NA
Common names Black bugbane, black snakeroot,
bugwort, rattleroot, rattletop,
rattleweed, macrotys
Black bugbane, black snakeroot,
bugwort, rattleroot, rattletop,
rattleweed, macrotys
Alfalfa, lucerne, purple medik,
trefoil
Boron
Proprietary product name (i.e.,
brand name) or extract name;
manufacturer
CimiPure (Naturex, Avignon,
France)
† † †
Is product authorized (licensed,
registered) in United States?
Yes, trademarked No trademark or
registration
No trademark or
registration
No trademark or
registration
Parts of plant used to produce the
product or extract
Rhizome and root Root Leaf NA
Type of product used (e.g., raw,
fresh, or dry, extract), type and
concentration of extraction
solvent, ratio of herbal drug to
extract
70% ethanol extract Water and alcohol 4:1 extract No solvents 4:1 extract NA
Method of authentication of raw
materials
GC TLC HPLC
Lot number of the raw material M008250 SB01-0160 220100-50 021390910
State whether a voucher specimen
(i.e., retention sample) retained;
if so, where it is kept or
deposited, and reference
number
Yes, voucher specimen 51680,
deposited at the New York
Botanical Garden
No—past time
of retention
No—past time
of retention
No—past time
of retention
Product dosage per capsule 80 mg 50 mg 100 mg 20 mg
Content (e.g., as weight,
concentration; may be given as
a range where appropriate) of
all quantified herbal product
constituents, both native and
added, per dosage unit form
Per capsule: 80 mg of black
cohosh, 510 mg of rice flour
Added materials (binders, fillers,
and other excipients)
Rice flour None None None
Standardization Triterpene glycosides None None Boron
Product’s chemical fingerprint and
methods used
HPLC, CE HPLC, CE HP-TLC HPLC, CE
For standardized products, quantity
of active/marker constituents
per dosage unit form
2.5% NA NA NA
Amount detected Triterpene glycosides, 3.125% Triterpene glycosides, 4.4% L-canavanine
Alfalfa juice, 20% extract, 1 mg/g
Alfalfa leaf, 4:1 extract, 3 mg/g
0.92 mg
Was a sample of the product (i.e.,
retention sample) retained? If
so, where it is kept or
deposited?
Yes
* All analyses were preformed by ConsumerLab.com. Specifics of special testing/purity testing are as follows (abbreviations used in tables defined at end of footnote): 1.
Chlorinated pesticide screens were tested on the black cohosh and the multibotanical finished products, evaluated by GC/MS. The detection limit level was set at 50 parts
per billion. The following were tested and were not found: pentacholorobenze, tetracholoroaniline, hexacholorobenzene, -benzene hexachloride (BHC), pentachloronitro-
benzene, lindane, -BHC, heptachlor, pentachloroaniline, -BHC, aldrin, pentachlorothioanisole, heptachlor, epoxide, -chlordane, endosulfan I, -chlordane, dieldrin,
endrin, endrin aldehyde, endosulfan sulfate, dichloro-diphenyl-trichloroethane, dichlorodiphenyldichloroethylene, dichloro-diphenyl-dichloroethane, endosulfan II, methoxy-
chlor, and endrine ketone. 2. Black cohosh, and the multibotanical were tested for heavy metals by inductively coupled plasma–mass spectroscopy. The black cohosh product
contained 0.06 g of lead, 0.06 g of cadmium, and 0.97 g of arsenic. The multibotanical finished product contained 0.49 g of lead, 0.0714 g of cadmium,
and 1.16 g of arsenic. 3. Alfalfa was tested for L-canavanine, an antinutrient, by using HP-TLC. The alfalfa leaf and juice extract raw material had 1 mg/g of L-canavanine
in the juice extract (20% extract) and 3 mg/g in the leaf (4:1 extract). 4. Screening for estrogenic drug substances was detected by GC/MS. The following were tested and
not found: diethylstilbestrol, estradiol, estrone, estriol, ethynyl estradiol, and tamoxifen. CE capillary electrophoresis; GC  gas chromatography; HPLC  high-perfor-
mance liquid chromatography; HP-TLC  high-performance thin-layer chromatography; MS  mass spectroscopy; NA  not available; TLC thin-layer chromatography.
† Progyne (Progena, Albuquerque, NM, Lot 1051504).
‡ Per capsule: 50 mg of black cohosh, 100 mg of alfalfa, 1 mg of boron citrate, 50 mg of chaste tree, 100 mg of dong quai, 50 mg of false unicorn, 50 mg of licorice, 100
mg of oats, 100 mg of pomegranate, 100 mg of siberian ginseng; no filler or other constituents.
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Appendix Table—Continued
Multibotanical Product
Chaste Tree Dong Quai False Unicorn Licorice Oats Straw Pomegranate Siberian Ginseng
Vitex agnus-castus Angelica
sinensis
Chamaelirium
luteum
Glycyrrhiza
glabra
Avena sativa Punica granatum Eleutherococcus
senticosus
Verbenaceae Apiaceae Liliaceae Fabaceae Poacaea Lythraceae Araliaceae
Chaste berry,
Monk’s pepper,
Abraham’s balm,
chaste lamb-tree,
safe tree,
Indian-spice,
wild pepper
Dong quai, dang
gui, tang-kuei
Starwort,
helonias root,
blazing star
root, devil’s
bit, false
unicorn
Lacrisse, sweet
licorice,
licorice root
Oats Pomegranate Ginseng
† † † † † † †
No trademark or
registration
No trademark or
registration
No trademark or
registration
No trademark or
registration
No trademark or
registration
No trademark or
registration
No trademark or
registration
Berry Root Root Root Straw Fruit Root
Dry powder Water and
alcohol 4:1
extract
Water and
alcohol 4:1
extract
Water and
alcohol 4:1
extract
Water and
alcohol 10:1
extract
Dry powder Water and
alcohol 0.8%
extract
GC GC TLC TLC GC GC GC
38699C SB01-0031 14C1-6 20012450 SB01-0136C-J L5029P SG001006C
No—past time of
retention
No—past time
of retention
No—past time
of retention
No—past time
of retention
No—past time
of retention
No—past time
of retention
No—past time of
retention
50 mg 100 mg 50 mg 50 mg 100 mg 100 mg 100 mg
‡ ‡ ‡ ‡ ‡ ‡ ‡
None None None None None None None
None None None None None None Eleutherosides B
and E
HPLC, CE HPLC, CE HPLC, CE HPLC, CE Not tested HP-TLC HPLC, CE
NA NA NA NA NA NA 0.8%
Agnuside, 0.024% Ligustilide,
0.001%;
ferulic acid,
0.016%
Diosgenin (free)
Not detected
Glycyrrhizic acid,
14%
Not tested Polyphenolics
Not detected
Eleutherosides B
and E, 1.6%
Yes—for both products, a retention sample is being stored at the Group Health Center for Health Studies
W-244 19 December 2006 Annals of Internal Medicine Volume 145 • Number 12 www.annals.org
Downloaded from https://annals.org by University of California San Diego user on 07/01/2019
